Practice Support Update Blog

FDA approves first RSV vaccine

May 24, 2023 1:51:50 PM / by Practice Support Team

The FDA approved the first vaccine (brand name "Arexvy") to prevent infection with Respiratory Syncytial  Virus (RSV). 

medicine vialsWho is this vaccine for? Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

When will it be available? Possibly late summer 2023 (well before the typical RSV season). FDA approval means the vaccine has been determined to be safe and effective in this age group. The next step is review by the Advisory Committee on Immunization Practice, which makes vaccine recommendations to the CDC. This committee is expected to meet in June 2023.

What about children or pregnant women?: Several other promising vaccine candidates are being developed and will be under review in coming months for these populations.

Want to learn more?

FDA approval press release

RSV vaccine: 4 questions answered ('The Conversation')


Tags: Vaccines, RSV, Adult health

  • There are no suggestions because the search field is empty.

Practice Support Services

Health care practices in North Carolina face many challenges. Our team of quality improvement coaches (QICs) have skills and expertise to support you in your transformation efforts.

To learn more about Practice Support Click Here

Apply for practice support services - fill out an application here

Subscribe to Blog Updates

Additional Resources:
Tip Sheets
Lib Guides
Interactive Resource Guides
Digital Library
New call-to-action
Join email list

Connect With Us:

Posts by Topic

See all

In Case You Missed It... Check Out These Recent Posts